- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Breaking Down the Data in Bladder Cancer With Drs Aggen, Grivas, and Shore
October 21st 2025, 3:30am
OncLive News Network: On Location at ESMO 2025
David H. Aggen, MD, PhD, Petros Grivas, MD, PhD, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in bladder cancer presented during the 2025 ESMO Congress.
Frontline EIK1001 Plus Chemoimmunotherapy Stimulates Antitumor Activity in Advanced NSCLC
October 20th 2025, 9:56pm
EIK1001 plus pembrolizumab and chemo showed a 64% ORR and manageable safety in first-line stage IV NSCLC, per phase 2 TeLuRide-005 data.
Zabilugene Almadenorepvec Plus SOC Therapy Yields OS Benefit in Untreated Metastatic PDAC
October 20th 2025, 9:31pm
Zabilugene almadenorepvec plus SOC therapy was active in patients with treatment-naive metasatic PDAC.
Zanzalintinib Plus Atezolizumab Improves OS in Previously Treated Metastatic CRC
October 20th 2025, 8:58pm
Zanzalintinib plus atezolizumab demonstrate potential chemotherapy-free option in previously treated metastatic CRC.
NADINA Trial Favors Neoadjuvant Nivolumab/Ipilimumab in Resectable Stage III Melanoma
October 20th 2025, 8:25pm
Neoadjuvant nivolumab plus ipilimumab proved superior to adjuvant nivolumab alone with longer follow-up data from the NADINA trial in stage III melanoma.
ctDNA-Guided Adjuvant Atezolizumab Boosts DFS, OS in Muscle-Invasive Bladder Cancer
October 20th 2025, 8:17pm
Adjuvant atezolizumab improved DFS and OS in patients with muscle-invasive bladder cancer who tested positive for ctDNA after radical cystectomy.
CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC
October 20th 2025, 7:59pm
Nivolumab plus ipilimumab improved PFS and response rates vs nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns.
Camrelizumab Plus Famitinib Extends PFS vs Chemotherapy in First-Line Metastatic Cervical Cancer
October 20th 2025, 7:45pm
ESMO Congress: Gynecologic Cancers
Camrelizumab plus famitinib led to superior PFS and OS outcomes vs chemotherapy in frontline recurrent/metastatic cervical cancer.
Bemarituzumab/Chemo Combo Translates to OS Advantage in FGFR2b+ Gastric/GEJ Cancer
October 20th 2025, 7:28pm
Bemarituzumab/mFOLFOX6 produced an OS advantage over placebo/mFOLFOX6 in FGFR2b-overexpressing gastric/GEJ cancer; this was attenuated at longer follow-up.
IO102-IO103 Plus Pembrolizumab Improves PFS in Treatment-Naive Advanced Melanoma
October 20th 2025, 6:50pm
IO102-IO103 plus pembrolizumab was associated with a clinically relevant improvement in median progression-free survival.
Dr Le on Early Efficacy Data With Sevabertinib Monotherapy in HER2-Mutant NSCLC
October 20th 2025, 4:56pm
Xiuning Le, MD, PhD, discusses findings from the phase 1/2 SOHO-01 trial evaluating sevabertinib monotherapy in HER2-mutant advanced NSCLC.
Dr Jänne on OS Benefit With Osimertinib Plus Chemo by Poor Prognostic Factors in EGFR+ NSCLC
October 20th 2025, 4:56pm
Pasi A. Jänne, MD, PhD, discusses OS outcomes with osimertinib with or without chemotherapy based on baseline prognostic factors in EGFR-mutant NSCLC.
Telisotuzumab Adizutecan Demonstrates Activity, Tolerability in Locally Advanced/Metastatic PDAC
October 20th 2025, 3:35pm
Telisotuzumab adizutecan displayed early activity in locally advanced/metastatic PDAC.
Perioperative Pembrolizumab Benefits Persist at 5-Year NSCLC Update
October 20th 2025, 3:17pm
Pembrolizumab before and after surgery reduced the risk of death compared with placebo for patients with early-stage non–small cell lung cancer.
Sacituzumab Govitecan Plus Pembrolizumab Upholds QOL, Delays Physical Decline in mTNBC
October 20th 2025, 2:50pm
Sacituzumab govitecan plus pembrolizumab may maintain quality of life in patients with previously untreated, PD-L1–positive metastatic TNBC.
Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer
October 20th 2025, 1:21pm
ESMO Congress: Gynecologic Cancers
Raludotatug deruxtecan demonstrates antitumor activity and manageable safety in platinum-resistant ovarian cancer.
DESTINY-Breast09 Subgroup Data Show Clinically Meaningful PFS Benefit T-DXd/Pertuzumab in HER2+ Breast Cancer
October 20th 2025, 12:18pm
T-DXd plus pertuzumab generated consistent PFS benefits among HER2+ breast cancer subgroups.
ADC Iza-Bren Generates Responses and Improves PFS vs Chemo in Metastatic NPC
October 19th 2025, 9:40pm
ESMO Congress: Head and Neck Cancer
The bispecific ADC iza-bren improved ORR and led to more durable responses vs chemotherapy in heavily pretreated recurrent or metastatic NPC.
Rounding Up Relevant Data in RCC With Drs Beckermann and Rini
October 19th 2025, 9:35pm
OncLive News Network: On Location at ESMO 2025
Brian I. Rini, MD, FASCO, and Katy Beckermann, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in renal cell carcinoma presented during the 2025 ESMO Congress.
Ivonescimab Plus Chemo Might Be a New SOC in Advanced Squamous NSCLC
October 19th 2025, 8:56pm
Ivonescimab plus chemotherapy improved PFS and response rates vs tislelizumab in advanced squamous NSCLC, with a manageable safety profile.